Company Analysis
Sign in

BioVie Inc. (BIVI)

Nasdaq: BIVI · Pharmaceutical Preparations · Carson City, NV · filing with the SEC since 2013
Full chart Alerts Compare
Grade4.6
◀ Past 3.3● Present 4.2▶ Future 5.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

3 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BioVie Inc.’s names, not what it holds today.

Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and none in 2023
Applications published
14
5 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'17'18'19'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
BioVie Inc. its own name
named as the applicant on its applications, in US
0 granted
13 published
BioVie, Inc. its own name
US, as the owner printed on each patent
3 granted
0 published
NanoAntibiotics, Inc. a former name
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 3, 202412,156,898Formulations of terlipressinPharmaceuticalsBioVie, Inc.
Jun 21, 202211,364,277Treatment of ascitesPharmaceuticalsBioVie, Inc.
May 23, 20179,655,945Treatment of ascitesPharmaceuticalsBioVie, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 6, 20252025/0340941ASSAY AND METHODS FOR DRUG DISCOVERYAnalysis of biological materialsBioVie Inc.
Oct 9, 20252025/0312410Treatment of AscitesPharmaceuticalsBioVie Inc.
Aug 21, 20252025/0262223METHODS FOR THE TREATMENT OF BIOLOGICAL AGINGPharmaceuticalsBioVie Inc.
Aug 7, 20252025/0249066Formulations of TerlipressinPharmaceuticalsBioVie Inc.
Jun 12, 20252025/0186458METHODS FOR THE TREATMENT OF MILD COGNITIVE IMPAIRMENTPharmaceuticalsBioVie Inc.
May 23, 20242024/0165193Treatment of AscitesPharmaceuticalsBioVie Inc.
Apr 4, 20242024/0108636COMPOSITIONS FOR TREATMENT OF NEURODEGENERATIVE CONDITIONSPharmaceuticalsBioVie Inc.
Aug 3, 20232023/0241156METHODS OF TREATING DISEASE WITH TERLIPRESSINPharmaceuticalsBioVie Inc.
May 11, 20232023/0146264Treatment of AscitesPharmaceuticalsBioVie Inc.
Jul 28, 20222022/0233634FORMULATIONS OF TERLIPRESSINPharmaceuticalsBioVie Inc. · patent 12,156,898 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 6 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BIVI · research, not advice